🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 74 of 116

  1. Timolol Micro Labs 5 mg/ml Augentropfen, Losung, Zink Verla® 10 mg, Filmtabletten, Doxy-M-ratiopharm 100 mg tabletės, Protopic 0.1% ointment, ClobeGalen 500 Mikrogramm/g Shampoo, JNJ-73841937, Dociton® 10 mg Filmtabletten, Doxy-M-ratiopharm® 100 mg Tabletten, JNJ-61186372, MINOCIN 50 mg capsule rigide, Minocyclin-ratiopharm® 100 mg Hartkapseln, Protopic 0.1% ointment, Timolol 0,5 % AT - 1 A Pharma, 5 mg/ml Augentropfen, Lösung, Doxyderma 50 mg, Opzelura 15 mg/g cream, JNJ-61186372, Chlorhexidine, Dalacin 10

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  2. Tipifarnib

    Kura Oncology

    Thyroid Cancer

    phase 2 small molecule completed

    1 trial

  3. Tipifarnib

    Kura Oncology

    Relapsed or Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  4. Tipifarnib

    Kura Oncology

    Leukemia, Myelomonocytic, Chronic

    phase 2 small molecule completed

    1 trial

  5. Tiragolumab

    Hoffmann-La Roche

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  6. Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

  7. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  8. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669

    Hoffmann-La Roche

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  9. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    RECTAL NEOPLASMS

    phase 2 small molecule active

    1 trial

  10. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thyroid Cancer

    phase 2 small molecule active

    1 trial

  11. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  13. Tislelizumab

    The First People's Hospital of Lianyungang

    Bladder Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  14. Tislelizumab

    The First People's Hospital of Lianyungang

    Biliary Tract Tumor

    phase 2 small molecule active

    1 trial

  15. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  16. Tislelizumab

    Hospital Authority, Hong Kong

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  17. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  18. Tislelizumab

    The First People's Hospital of Lianyungang

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  19. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Cancer

    phase 2 small molecule terminated

    1 trial

  21. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Unresectable Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. Tislelizumab

    BeiGene

    Cervical Cancer

    phase 2 mab completed

    1 trial

  23. Tislelizumab

    The First People's Hospital of Lianyungang

    HER2-positive or Mutated Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  24. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  25. Tislelizumab (BGB-A317)

    BEONE MEDICINES AUS PTY LTD

    MSI-H/dMMR Solid Tumors

    phase 2 small molecule active

    1 trial

  26. Tislelizumab combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  27. TmBU conditioning Regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  28. Tolecizumab (PCSK9 Inhibitor)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colon Adenocarcinoma

    phase 2 small molecule active

    1 trial

  29. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

  30. Toripalimab

    Yongchang Zhang

    Advanced Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  31. Toripalimab

    The First People's Hospital of Lianyungang

    Urinary Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  32. Toripalimab

    Coherus Oncology

    Sinonasal Cancer

    phase 2 small molecule active

    1 trial

  33. Toripalimab

    Coherus Oncology

    Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

    phase 2 small molecule active

    1 trial

  34. Toripalimab

    The First People's Hospital of Lianyungang

    Small Cell Lung Cancer Limited Stage

    phase 2 small molecule terminated

    1 trial

  35. Toripalimab

    Coherus Oncology

    Localized Colon Carcinoma

    phase 2 small molecule active

    1 trial

  36. Toripalimab

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  37. Toripalimab

    The First People's Hospital of Lianyungang

    Locally Advanced Colon Cancer

    phase 2 small molecule active

    1 trial

  38. Toripalimab

    The First People's Hospital of Lianyungang

    Pancreatic Carcinoma

    phase 2 small molecule active

    1 trial

  39. Toripalimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  40. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tracheal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  41. Toripalimab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  42. Toripalimab

    The First People's Hospital of Lianyungang

    Adenocarcinoma of the Stomach

    phase 2 small molecule active

    1 trial

  43. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Triple-Negative Breast Cancer (TNBC)

    phase 2 small molecule active

    1 trial

  44. Toripalimab + Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thymic Epithelial Tumor

    phase 2 small molecule active

    1 trial

  45. Toripalimab + Chemotherapy

    Coherus Oncology

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  46. Toripalimab+Nedaplatin+Albumin Paclitaxel

    The First People's Hospital of Lianyungang

    Locally Advanced Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  47. Toripalimab-tpzi

    Coherus Oncology

    Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  48. Total Neoadjuvant Treatment

    The First People's Hospital of Lianyungang

    Biliary Tract Neoplasms

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.